SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry. 1981; 38: 527533.
  • 2
    Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med. 1983; 45: 333339.
  • 3
    Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989; 2: 888891.
  • 4
    Kogon MM, Biswas A, Pearl D, Carlson RW, Spiegel D. Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Cancer. 1997; 80: 225230.
  • 5
    Kuchler T, Henne-Bruns D, Rappat S, et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. Hepatogastroenterology. 1999; 46: 322335.
  • 6
    McCorkle R, Strumpf NE, Nuamah IF, et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatrics Soc. 2000; 48: 17071713. Comment in: J Am Geriatr Soc. 2000; 48: 1732–1733.
  • 7
    Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry. 1993; 50: 681689.
  • 8
    Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry. 2003; 60: 100103.
  • 9
    Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol. 1990; 8: 356364.
  • 10
    Linn MW, Linn BS, Harris R. Effects of counseling for late stage cancer. Cancer. 1982; 49: 10481055.
  • 11
    Ilnyckyj A, Farber J, Cheang M, Weinerman B. A randomized controlled trial of psychotherapeutic intervention in cancer patients. Ann R Coll Phys Surg Can. 1994; 27: 9396.
  • 12
    Edelman S, Lemon J, Bell DR, Kidman AD. Effects of group CBT on the survival time of patients with metastatic breast cancer. Psychooncology. 1999; 8: 474481.
  • 13
    Cunningham AJ, Edmonds CVI, Jenkins GP, Pollack H, Lockwood GA, Warr D. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psychooncology. 1998; 7: 508517.
  • 14
    Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med. 2001; 345: 17191726.
  • 15
    Kissane DW, Love A, Hatton A, et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol. 2004; 22: 42554260.
  • 16
    Spiegel D. Effects of psychotherapy on cancer survival. Nat Rev Cancer. 2002; 2: 383389.
  • 17
    Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst. 2002; 94: 558584.
  • 18
    Chow E, Tsao MN, Harth T. Does psychosocial intervention improve survival in cancer? A meta-analysis. Palliat Med. 2004; 18: 2531.
  • 19
    Edwards AG, Hailey S, Maxwell M. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev. 2004: CD004253. Comment in: Evid Based Nurs. 2004; 7: 110.
  • 20
    Smedslund G, Ringdal GI. Meta-analysis of the effects of psychosocial interventions on survival time in cancer patients. J Psychosom Res. 2004; 57: 123131; discussion, 133–135.
  • 21
    Spiegel D. Commentary on meta-analysis of the effects of psychosocial interventions on survival time and mortality in cancer patients by Geir Smedslund and Gerd Inger Ringdal. J Psychosom Res. 2004; 57: 133135.
  • 22
    Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003; 54: 269282.
  • 23
    Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005; 58: 175189.
  • 24
    Classen C, Butler LD, Koopman C, et al. Supportive-expressive group therapy and distress in patients with metastatic breast cancer: a randomized clinical intervention trial. Arch Gen Psychiatry. 2001; 58: 494501.
  • 25
    Efron B. Forcing a sequential experiment to be balanced. Biometrika. 1971; 58: 403417.
  • 26
    Spiegel D, Classen C. Group Therapy for Cancer Patients: A Research-Based Handbook of Psychosocial Care. New York: Basic Books; 2000.
  • 27
    Spiegel H, Spiegel D. Trance and Treatment: Clinical Uses of Hypnosis. Washington, DC: American Psychiatric Publishing; 2004.
  • 28
    Giese-Davis J, Koopman C, Butler LD, et al. Change in emotion-regulation strategy for women with metastatic breast cancer following supportive-expressive group therapy. J Consult Clin Psychol. 2002; 70: 916925.
  • 29
    Kraemer HC, Robinson TN. Are certain multicenter randomized clinical trial structures misleading clinical and policy decisions? Contemp Clin Trials. 2005; 26: 518529.
  • 30
    Kraemer HC, Blasey CM. Centering in regression analyses: a strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res. 2004; 13: 141151.
  • 31
    Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000; 355: 1822.
  • 32
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 16871717. Comments in: ACP J Club. 2005; 143: 58. Lancet. 2005; 365: 1665–1666.
  • 33
    Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006; 296: 12861289.
  • 34
    Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry. 2001; 158: 848856.
  • 35
    Kraemer HC. Pitfalls of multisite randomized clinical trials of efficacy and effectiveness. Schizophr Bull. 2000; 26: 533541.
  • 36
    Yalom ID, Greaves C. Group therapy with the terminally ill. Am J Psychiatry. 1977; 134: 396400.
  • 37
    Fox BA. A hypothesis about Spiegel et al.'s 1989 paper on psychosocial intervention and breast cancer survival. Psychooncology. 1998; 7: 361370.
  • 38
    Goodwin PJ, Pritchard KI, Spiegel D. The Fox guarding the clinical trial: internal vs. external validity in randomized studies [letter]. Psychooncology. 1999; 8: 275. Comment in: Psychooncology. 1999; 8: 366–367.
  • 39
    Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. Psychooncology. 2007; 16: 227286.
  • 40
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med. 2003; 348: 618629.
  • 41
    Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003; 348: 24312442.
  • 42
    Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006; 295: 16581667.
  • 43
    Chlebowski RT, Blackburn GL, Elashoff RE, et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) [abstract]. ASCO Meeting Abstracts. 2005; 23: 10.
  • 44
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747752.
  • 45
    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100: 84188423.
  • 46
    Kristensen VN, Sorlie T, Geisler J, et al. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. Clin Cancer Res. 2005; 11(2 pt 2): 878s883s.
  • 47
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 1086910874.
  • 48
    Gore-Felton C, Spiegel D. Enhancing women's lives: the role of support groups among breast cancer patients. J Spec Group Work. 1999; 24: 274287.
  • 49
    Pohls UG, Renner SP, Fasching PA, et al. Awareness of breast cancer incidence and risk factors among healthy women. Eur J Cancer Prev. 2004; 13: 249256.